Daiichi Sankyo Company, Limited

(PINK:DSKYF)

Latest On Daiichi Sankyo Company, Limited (DSKYF):

Date/Time Type Description Signal Details
2021-04-20 15:04 ESTNewsAstraZeneca's Enhertu now available in U.K. for breast cancerN/A
2021-03-30 06:02 ESTDividendA dividend of $13.5 has been announced on Apr 27, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021.Neutral
2021-02-21 03:29 ESTNewsTakeda and Daiichi Sankyo to begin COVID-19 vaccine trials in JapanN/A
2021-02-01 08:53 ESTEarnings EstimateAn EPS average of $0.10 is estimated for the quarter ending on June 30, 2021.Sell
2021-01-31 08:56 ESTFinancialsCompany financials have been released.Neutral
2021-01-29 09:47 ESTNewsDaiichi Sankyo reports Q3 resultsN/A
2021-01-20 10:38 ESTNewsEU OK's AstraZeneca, Daiichi Sankyo's Enhertu for breast cancerN/A
2021-01-15 18:24 ESTNewsAstraZeneca's antibody drug conjugate Enhertu wins expanded approval from the FDAN/A
2020-12-10 21:45 ESTNewsAZN/Daiichi Sankyo' Enhertu scores ‘impressive’ new data in HER2 breast cancer studyN/A
2020-11-26 22:23 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 01:32 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:48 ESTFinancialsCompany financials have been released.Neutral
2020-11-02 09:19 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 07:35 ESTNewsAstraZeneca/Daiichi antibody-drug conjugate nabs accelerated review in U.S. for certain type of stomach cancerN/A
2020-11-01 07:31 ESTNewsDaiichi Sankyo Co. reports 1H resultsN/A
2020-09-26 14:48 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:53 ESTFinancialsCompany financials have been released.Neutral
2020-09-03 06:53 ESTNewsDaiichi inks milademetan license deal with Rain TherapeuticsN/A
2020-08-21 08:49 ESTNewsImmunic launches early-stage study of IMU-856 in gastrointestinal disordersN/A
2020-08-14 10:49 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 06:42 ESTNewsDaiichi teams up with AstraZeneca in lung cancer studyN/A
2020-08-06 10:10 ESTFinancialsCompany financials have been released.Neutral
2020-08-04 01:56 ESTNewsRedHill Bio inks new agreement with Daiichi Sankyo for MovantikN/A
2020-08-03 06:07 ESTFinancialsCompany financials have been released.Neutral
2020-08-03 06:07 ESTEarnings EstimateAn EPS average of $0.62 is estimated for the quarter ending on December 31, 2020.Buy
2020-07-31 11:42 ESTNewsDaiichi Sankyo reports Q1 resultsN/A
2020-07-30 18:34 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 06:31 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 22:42 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 14:24 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 11:04 ESTNewsAstrazeneca inks $6B oncology deal with Daiichi SankyoN/A
2020-07-23 19:11 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 10:38 ESTFinancialsCompany financials have been released.Neutral
2020-07-07 06:06 ESTEarnings EstimateAn EPS average of $13.00 is estimated for the quarter ending on September 30, 2020.Buy
2020-07-01 18:24 ESTFinancialsCompany financials have been released.Neutral
2020-06-27 06:57 ESTNewsEuropean advisory group thumbs down on Daiichi's pexidartinibN/A
2020-06-23 17:42 ESTNewsThermo Fisher to develop Enhertu companion diagnostic with Daiichi SankyoN/A
2020-06-19 14:16 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 06:21 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 07:55 ESTFinancialsCompany financials have been released.Neutral
2020-05-29 23:45 ESTNewsAstraZeneca antibody-drug conjugate shows positive effect in gastric cancerN/A
2020-05-27 06:57 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 02:31 ESTFinancialsCompany financials have been released.Neutral
2020-05-09 16:56 ESTNewsDaiichi files application in Japan for antibody-drug conjugate for gastric cancerN/A
2020-05-06 07:09 ESTFinancialsCompany financials have been released.Neutral
2020-05-04 14:17 ESTFinancialsCompany financials have been released.Neutral
2020-05-02 00:15 ESTNewsDaiichi Sankyo Co Ltd (DSKYF) CEO Sunao Manabe on Q4 2020 Results - Earnings Call TranscriptN/A
2020-05-01 18:09 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 06:22 ESTFinancialsCompany financials have been released.Neutral
2020-04-29 14:04 ESTStock SplitA stock split will occur on Sep 29, 2020 with a split factor of 3:1.Neutral

About Daiichi Sankyo Company, Limited (DSKYF):

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. The company was founded in 1899 and is headquartered in Tokyo, Japan.

See Advanced Chart

General

  • Name Daiichi Sankyo Company, Limited
  • Symbol DSKYF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-General
  • Full Time Employees 15,348
  • Last Split Factor3:1
  • Last Split Date2020-09-29
  • Fiscal Year EndMarch
  • Web URLhttp://www.daiichisankyo.com
View More

Valuation

  • Trailing PE 32.41
  • Forward PE 111.11
  • Price/Sales (Trailing 12 Mt.) 6.81
  • Price/Book (Most Recent Quarter) 5.02
  • Enterprise Value Revenue 0.05
  • Enterprise Value EBITDA 0.37
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $0.27
  • Next Year EPS Estimate $0.37
  • Next Quarter EPS Estimate -$0.10
  • Profit Margin 7%
  • Return on Assets 2%
  • Return on Equity 5%
  • Earnings Per Share $0.97
  • Revenue Per Share $0
  • Gross Profit 638.59 billion
  • Quarterly Earnings Growth -6.8%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 26.47
  • Environment Score 2.42
  • Social Score 15.42
  • Governance Score 10.47
  • Controversy Level 1
View More

Highlights

  • Market Capitalization 59.67 billion
  • PEG Ratio 31575.3
  • Analyst Target Price $13
  • Book Value Per Share $17.50
View More

Share Statistics

  • Shares Outstanding 1.92 billion
  • Shares Float 1.93 billion
  • % Held by Insiders 102%
  • % Held by Institutions 45.07%
View More

Technicals

  • Beta 0.92
  • 52 Week High $36.78
  • 52 Week Low $21.26
  • 50 Day Moving Average 30.74
  • 200 Day Moving Average 31.43
View More

Dividends

  • Forward Annual Dividend Yield 0.47%
  • Payout Ratio 76%
  • Dividend Date 2011-12-01
  • ExDividend Date 2018-03-28
  • Dividend Per Share $0.64
  • Dividend Yield 0%
View More

Daiichi Sankyo Company, Limited (DSKYF) Dividend Calendar:

DSKYF's last dividend payment was made to shareholders on December 1, 2011.
Daiichi Sankyo Company, Limited pays out 76% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount
2020-09-292020-12-012020-09-302020-04-27$40.5
2020-03-302020-06-162020-03-312019-04-25$35
2019-09-272019-12-022019-09-302019-04-25$35
2019-03-292019-06-182019-03-312018-04-27$35
2018-09-282018-12-032018-09-302018-04-27$35
2018-03-292018-06-192018-03-312017-05-11$35
2017-03-302017-06-202017-03-312016-05-12$35
2016-09-292016-12-012016-09-302016-05-12$35
2016-03-302016-06-212016-03-312015-05-14$30
2021-03-300000-00-002021-03-312020-04-27$13.5
2020-03-302020-03-312019-04-25$35

Daiichi Sankyo Company, Limited (DSKYF) Earnings Estimates:

An earnings estimate is an analyst's estimate for a company's future quarterly or annual earnings per share (EPS). Future earnings estimates are arguably the most important data when attempting to value a firm.

DSKYF's EPS estimate for the current year is $0.27
Date Number of Analysts Average Estimate Low Estimate High Estimate
2021-06-301$0.10$0.10$0.10

Daiichi Sankyo Company, Limited (DSKYF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

DSKYF's next estimated earnings release date is June 30, 2021.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A$0.11$0.14-21.43%
2020-09-302020-12-31$N/A$0.12$4.33-97.22%
2020-06-302020-09-30$N/A$0.10$15.27-99.37%
2020-03-312020-06-30$N/A$0.15-$20.31100.75%
2019-12-312020-03-31$2.55 billion-$0.02
2019-09-302019-12-31$2.13 billion$0.33
2019-06-302019-09-30$2.3 billion$0.10$9.30-98.92%
2019-03-312019-06-30$2.04 billion$0.21
2018-12-312019-03-31$2.34 billion$0.07
2018-09-302018-12-31$1.94 billion$0.16
2018-06-302018-09-30$2.04 billion$0.09
2018-03-312018-06-30$2.07 billion$0.11-$11.30100.98%
2017-12-312018-03-31$2.41 billion-$0.06$29.00-100.2%
2017-09-302017-12-31$2.04 billion$0.17$24.30-99.3%
2017-06-302017-09-30$2.13 billion$0.02$38.50-99.94%
2017-03-312017-06-30$220.72 billion$0.13-$12.50101.04%
2016-12-312017-03-31$276.39 billion-$0.16$19.10-100.82%
2016-09-302016-12-31$0.17$24.00-99.3%
2016-06-302016-09-30$0.09$27.50-99.68%
2016-03-312016-06-30$0.15-$35.80100.41%
2015-12-312016-03-31-$0.12$10.20-101.21%
2015-09-302015-12-31$0.16
2015-06-302015-09-30$0.14$28.30-99.49%
2015-03-312015-06-30$0.14$0.00
2014-12-312015-03-31-$0.09$10.40-100.85%
2014-09-302014-12-31$0.20$11.80-98.27%
2014-06-302014-09-30$0.13
2014-03-312014-06-30$0.09$8.50-98.9%
2013-12-312014-03-31-$0.06$0.29-122.14%
2013-09-302013-12-31$0.20
2013-06-302013-09-30$0.10
2013-03-312013-06-30$0.05
2012-12-312013-03-31$0.08
2012-09-302012-12-31$0.15
2012-06-302012-09-30$0.02
2012-03-312012-06-30$0.12
2011-12-312012-03-31-$0.04
2011-09-302011-12-31-$0.12
2011-06-302011-09-30$0.07
2011-03-312011-06-30$0.15
2010-12-312011-03-31-$0.05
2010-09-302010-12-31$0.16
2010-06-302010-06-30$0.17

Daiichi Sankyo Company, Limited (DSKYF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Daiichi Sankyo Company, Limited (DSKYF) Chart:

Daiichi Sankyo Company, Limited (DSKYF) News:

Below you will find a list of latest news for Daiichi Sankyo Company, Limited (DSKYF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Daiichi Sankyo Company, Limited (DSKYF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Daiichi Sankyo Company, Limited (DSKYF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link